
The CEO of Spero Therapeutics sold $207k of stock
Source link
Amentum misses initial and lower estimates; reaffirms the outlook for fiscal year 26
Amentum misses initial and lower estimates; reaffirms the outlook for fiscal year 26 Source link

The CEO of Spero Therapeutics sold $207k of stock
Source link
Amentum misses initial and lower estimates; reaffirms the outlook for fiscal year 26 Source link
Form 144 Roivant Sciences Ltd. For: 9 February Source link